+239.0%
MRVL vs GSK
+22.9%
+216.1%
-48.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.4% | -1.0% | -2.4% | -3.6% |
| 7D | +8.7% | -5.4% | +14.1% | +7.7% |
| 30D | +6.9% | -4.6% | +11.5% | +6.1% |
| 3M | -10.1% | -5.1% | -5.0% | -10.9% |
| 6M | +143.4% | -11.4% | +154.9% | +142.5% |
| YTD | +167.5% | +0.7% | +166.7% | +170.3% |
| 1Y | +239.0% | +23.0% | +215.9% | +261.0% |
| All | +239.0% | +22.9% | +216.1% | +261.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling